Larry Z Liu

Author PubWeight™ 34.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005 5.91
2 Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther 2006 2.86
3 Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med 2006 2.51
4 Medication adherence: a call for action. Am Heart J 2011 1.85
5 Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 2006 1.56
6 Variation in lung cancer risk by smoky coal subtype in Xuanwei, China. Int J Cancer 2008 1.45
7 Effects of the ritonavir price increase on the cost of protease inhibitor regimens in United States. Manag Care Interface 2006 1.38
8 Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006 1.37
9 Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol 2009 1.04
10 The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood) 2012 1.01
11 Determining initial and follow-up costs of cardiovascular events in a US managed care population. BMC Cardiovasc Disord 2011 0.97
12 Generic and therapeutic statin switches and disruptions in therapy. Curr Med Res Opin 2009 0.96
13 A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin Ther 2007 0.95
14 Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care 2007 0.94
15 Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. Am J Ther 2010 0.89
16 Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin 2008 0.89
17 Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther 2008 0.88
18 Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective. Curr Med Res Opin 2007 0.83
19 Dietary factors, food contamination and lung cancer risk in Xuanwei, China. Lung Cancer 2008 0.82
20 History of lung disease and risk of lung cancer in a population with high household fuel combustion exposures in rural China. Lung Cancer 2013 0.81
21 Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. Int J Gen Med 2013 0.79
22 The utility of observational studies in clinical decision making: lessons learned from statin trials. Postgrad Med 2010 0.78
23 The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag Care Interface 2007 0.78
24 Coal mining is associated with lung cancer risk in Xuanwei, China. Am J Ind Med 2011 0.78
25 Potential Clinical and Economic Impact of Switching Branded Medications to Generics. Am J Ther 2017 0.78
26 An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics 2008 0.77
27 Prophylaxis against venous thromboembolism in hospitalized medically ill patients. Circ Cardiovasc Qual Outcomes 2013 0.77
28 A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease. Diabetes Res Clin Pract 2008 0.75
29 Cost of venous thromboembolism in hospitalized medically ill patients. Am J Health Syst Pharm 2013 0.75
30 A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease. Am J Ther 2011 0.75
31 Pharmacological Prophylaxis for Venous Thromboembolism Among Hospitalized Patients With Acute Medical Illness: An Electronic Medical Records Study. Am J Ther 2016 0.75
32 Pharmacologic Prophylaxis for Venous Thromboembolism Among Patients With Total Joint Replacement: An Electronic Medical Records Study. Am J Ther 2016 0.75